MEDIAN Technologies Vendor's profile


mRECIST is now recommended by the European Association for the Study of the Liver(EASL) for clinical studies on advanced hepatocellular carcinoma (HCC) as it better fits disease evolution assessment than standard RECIST does.However, mRECIST for HCCis more complex than RECIST. Its management in c...


Contact MEDIAN Technologies

Title *
Company / organisation *
Firstname *
Job title *
Lastname *
City *
E-mail *
Country *
Comment


All information that you supply is protected by our privacy policy.
In order to provide you with this free service, we may share your business information with companies whose content you choose to view on this website.
By submitting your information you agree to our Terms of Use. - See more at: IMAIOS privacy policy


To feature here :  Get in touch